Pharmaceutical industry medical communications departments: Regulatory and legal perils and pitfalls

Drug Information Journal

Volumn 34, Issue 4, 2000, Pages 1009-1015

  Salter, F J ^a   Kramer, P F ^a   Palmer Shevlin, N L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Legal; Medical communications; PIDICs; Regulatory

Indexed keywords

DRUG INDUSTRY; DRUG INFORMATION; HEALTH CARE PERSONNEL; INFORMATION SCIENCE; LEGAL ASPECT; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

EID: 0033711601     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400403     Document Type: Review

References (10)

1. Drug information
2. The federal regulation of prescription drug advertising and promotion
3. Drug regulation, off-label uses and CME-reconciling competing values
4. Guidance for industry - Industry-supported scientific and educational activities
5. 21 CFR parts 16 and 99 - Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices; final rule
6. Bristol-Myers Squibb drug information department services
7. The state of the art, and future directions of drug information centers
8. Pharmacy law. Liability of drug information centers